| Ovarian carcinoma is the leading cause of gynecologic cancer deathesin the world. One of the major issues facing investigators is the optimaltreatment of patient with platinum-refractory ovarian cancer. It is said thatHSP70 , mtP53 are associated with chemotherapy resistantce. Theadenovirus with the E1B55-kd gene deleted, allowing selective replicationin and lysis of P53-deficient tumor cells, has shown preclinical efficacy . Inaddition, HSP70 can combined with tumor antigen peptide,HSP-antigencomplex(HAC),which can react immunoreaction. My trial is to proceeda deep research in order to provide a base for the therapy of adenovirusplus cisplatin-based Chemotherapy in ovarian cancer. Objective: This study was undertaken to examine the expression ofHSP70 and mutant type P53 in patients with princeps and recurrentepithelial ovarian cancer. In addition, this study was designed to discuss theclinical value of them in use of E1B-deleted adenovirus pluscisplatin-based chemotherapy on patients with epithelial ovariancarcinoma. Method: Paraffin-embedded tissue section were obtained from 59patients with epithelial ovarian cancer. Expression of P53 and HSP70 wasevaluated by immunohistochemical method. Expression of HSP70 inplasma from 31 patients with epithelial ovarian cancer was done by westernblot method to compare the intensity of different periods. Results: 1.Positive staining of HSP70 was detected in benign ,borderlinemalignancy and malignant tissues and the rates were 20%(2/10) ,46.67%(7/15)and 67.80%(40/59), respectively. The latter was significantlyhigher than the former. Immunohistochemical reactivity against anti-HSP70antibody was observed in the nucleus and cytoplasm. HSP70 positivity wassignificantly higher in recurrent cancer(78.26%,18/23)than in princepscancer(61.11%,22/36).We also found that positivity was significantlylower in stageâ… -â…¡and G2 cancer than in â…¢-â…£ and G3 invasive cancer. 2.Positive staining of mtP53 was detected in benign ,borderlinemalignancy and malignant tissues and the rates were 0%(0/10),33.33%(5/15)and 62.71%(37/59), respectively. The latter was significantlyhigher than the former. Immunohistochemical localization of mtP53 wasobserved in the nucleus. MtP53 positivity was significantly higher inrecurrent cancer(78.26%,18/23)than in princeps cancer(52.78%,19/36).We also found that positivity was significantly higher in advanced stage andlow grade cancer than in earlier stage and high grade cancer. 3.Furthermore, there was significant correlation between mtP53positivity and the expression of HSP70. In ovarian cancer ,the rate of mtP53positivity with HSP70 positivity was 55.9%(33/59).In 39 cases mtP53positivity ovarian cancer, there were 33 cases HSP70 positivity. In recurrentovarian cancer ,the rate of mtP53 positivity with HSP70 positivity was69.57%(16/23),which was significantly higher than in princeps cancer(47.22%,17/36). HSP70 positivity and P53 positivity were significantlyhigher in cisplatin-resist ovarian cancer(87.5%,14/16;87.5%,14/16)than not cisplatin-resist cancer(57.14%,4/7;42.86%,3/7). 4.Expression of HSP70 in the plasma was significantly higher whenafter surgery 2-4d and after chemotherapy 2d. After surgery 6d and afterchemotherapy 4d , the level of HSP70 comeback the normal. Conclusion: 1.Positive staining of HSP70 and mtP53 was correlated with clinicalstage and differential grade. Expression of HSP70 and mtP53 in ovariancarcinoma could be reliable indicators of prognosis. 2.These data from this study suggested that HSP70 positivity and P53positivity were significantly higher in cisplatin-resist ovarian cancer thannot cisplatin-resist cancer .Furthermore, there was significant relationbetween the expression of mtP53 and HSP70 in epithelial ovarian cancer,especially in recurrent cancer, which indicate that mtP53 and HSP70maybe play a important role in the development of recurrent ovarian cancer.Replication-selective adenoviruses are being developed as novel anticancertherapeutics to refractory ovarian cancer 3.Expression of HSP70 in the plasma was signifi...
|
PDF Full Text Request